$5.46
+0.07
(+1.37%)▲
0.18%
Downside
Day's Volatility :3.54%
Upside
3.36%
47.01%
Downside
52 Weeks Volatility :52.17%
Upside
9.75%
Period | Genfit Sa | Index (Russel 2000) |
---|---|---|
3 Months | 23.82% | 0.0% |
6 Months | 55.67% | 0.0% |
1 Year | 79.54% | 0.0% |
3 Years | 46.76% | -21.4% |
Market Capitalization | 268.8M |
Book Value | $1.96 |
Earnings Per Share (EPS) | 0.41 |
PE Ratio | 13.14 |
Profit Margin | 27.68% |
Operating Margin TTM | 51.0% |
Return On Assets TTM | 6.51% |
Return On Equity TTM | 25.91% |
Revenue TTM | 80.5M |
Revenue Per Share TTM | 1.62 |
Quarterly Revenue Growth YOY | 304.4% |
Gross Profit TTM | 26.2M |
EBITDA | 21.9M |
Diluted Eps TTM | 0.41 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 78.5K | ↓ 41.53% |
Net Income | -90.5M | ↑ 35.69% |
Net Profit Margin | -115.2K% | ↓ 65583.42% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 34.3M | ↑ 44594.2% |
Net Income | -72.4M | ↓ 18.08% |
Net Profit Margin | -211.24% | ↑ 115036.59% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 930.5K | ↓ 97.52% |
Net Income | -123.1M | ↑ 55.38% |
Net Profit Margin | -13.2K% | ↓ 13020.26% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 90.5M | ↑ 10366.54% |
Net Income | 76.0M | ↓ 166.45% |
Net Profit Margin | 84.0% | ↑ 13315.5% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 21.4M | ↓ 74.78% |
Net Income | -25.1M | ↓ 135.27% |
Net Profit Margin | -117.45% | ↓ 201.45% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 31.2M | ↑ 41.45% |
Net Income | -31.5M | ↑ 21.81% |
Net Profit Margin | -101.15% | ↑ 16.3% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 7.6M | ↑ 23.97% |
Net Income | -10.4M | - |
Net Profit Margin | -138.0% | - |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 11.5M | ↑ 51.96% |
Net Income | -20.9M | ↑ 100.0% |
Net Profit Margin | -181.62% | ↓ 43.62% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.0M | ↓ 75.46% |
Net Income | -4.3M | ↓ 80.72% |
Net Profit Margin | -142.65% | ↑ 38.97% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 17.1M | ↑ 19.75% |
Net Income | -8.0M | - |
Net Profit Margin | -47.06% | - |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 261.0M | ↓ 21.73% |
Total Liabilities | 237.2M | ↑ 10.36% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 344.3M | ↑ 35.03% |
Total Liabilities | 250.9M | ↑ 8.27% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 241.6M | ↓ 35.9% |
Total Liabilities | 261.2M | ↓ 4.88% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 318.5M | ↑ 41.84% |
Total Liabilities | 183.8M | ↓ 24.28% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 228.1M | ↓ 23.49% |
Total Liabilities | 128.1M | ↓ 25.59% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 173.3M | ↓ 19.58% |
Total Liabilities | 105.9M | ↓ 12.47% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 228.1M | - |
Total Liabilities | 128.1M | - |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 207.5M | ↓ 10.04% |
Total Liabilities | 127.8M | ↓ 1.34% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 210.3M | ↑ 0.0% |
Total Liabilities | 129.5M | ↑ 0.0% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 173.9M | ↓ 10.33% |
Total Liabilities | 105.9M | ↓ 11.28% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 189.7M | ↑ 0.0% |
Total Liabilities | 115.5M | ↑ 0.0% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 173.3M | ↓ 0.3% |
Total Liabilities | 105.9M | ↑ 0.0% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -63.8M | ↑ 12.49% |
Investing Cash Flow | -4.5M | ↑ 35.21% |
Financing Cash Flow | -7.4M | ↓ 103.74% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -53.0M | ↓ 14.98% |
Investing Cash Flow | 363.4K | ↓ 108.2% |
Financing Cash Flow | 129.9M | ↓ 1893.98% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -117.2M | ↑ 102.12% |
Investing Cash Flow | -1.2M | ↓ 395.41% |
Financing Cash Flow | -10.0M | ↓ 107.06% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 112.9M | ↓ 203.68% |
Investing Cash Flow | -3.8M | ↑ 249.59% |
Financing Cash Flow | -10.1M | ↑ 7.99% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -12.6M | ↓ 74.1% |
Investing Cash Flow | 1.3M | ↓ 1447.74% |
Financing Cash Flow | -921.5K | ↑ 2.05% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -12.5M | ↓ 0.26% |
Investing Cash Flow | 1.3M | ↑ 0.0% |
Financing Cash Flow | -882.0K | ↓ 4.29% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -12.5M | ↑ 0.0% |
Investing Cash Flow | 1.3M | ↑ 0.0% |
Financing Cash Flow | -882.0K | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -25.8M | ↑ 106.13% |
Investing Cash Flow | 1.3M | ↑ 0.0% |
Financing Cash Flow | -995.0K | ↑ 12.81% |
Sell
Neutral
Buy
Genfit Sa is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Genfit Sa | 31.37% | 55.67% | 79.54% | 46.76% | -60.4% |
Regeneron Pharmaceuticals, Inc. | -11.53% | 7.92% | 21.76% | 83.48% | 256.87% |
Novo Nordisk A/s | -12.73% | -9.68% | 25.05% | 134.03% | 343.37% |
Alnylam Pharmaceuticals, Inc. | 5.86% | 71.74% | 59.21% | 32.07% | 248.13% |
Vertex Pharmaceuticals Incorporated | -3.35% | 12.64% | 28.18% | 152.92% | 164.64% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Genfit Sa | 13.14 | 13.14 | NA | 0.0 | 0.26 | 0.07 | NA | 1.96 |
Regeneron Pharmaceuticals, Inc. | 26.81 | 26.81 | 1.38 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 38.76 | 38.76 | 1.75 | 3.39 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.55 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Genfit Sa | Buy | $268.8M | -60.4% | 13.14 | 27.68% |
Regeneron Pharmaceuticals, Inc. | Buy | $111.6B | 256.87% | 26.81 | 32.04% |
Novo Nordisk A/s | Buy | $512.4B | 343.37% | 38.76 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.4B | 248.13% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 164.64% | 32.84 | -4.74% |
Insights on Genfit Sa
Revenue is up for the last 3 quarters, 2.81M → 17.08M (in $), with an average increase of 48.4% per quarter
Netprofit is down for the last 2 quarters, -4.01M → -8.03M (in $), with an average decrease of 100.0% per quarter
Morgan Stanley - Brokerage Accounts
OLD MISSION CAPITAL LLC
genfit is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as nash - nonalcoholic steatohepatitis) or the bowel (such as the inflammatory bowel disease). genfit is committed to contribute to bringing new medicines to market for patients who lack suitable solutions, and strives to implement mutually beneficial approaches that combine novel drugs and biomarkers. its research programs have resulted in the creation of a rich and diversified pipeline of drug candidates, including genfit’s lead proprietary compound, gft505, that is completing a phase 2b study in nash.
Organization | Genfit Sa |
Employees | 169 |
CEO | Mr. Jean-Francois Mouney |
Industry | Biotechnology |
Generations Bancorp Ny Inc
$5.46
+1.37%
Innovator Us Equity Accelerated Etf - April
$5.46
+1.37%
First Trust Exchange-traded
$5.46
+1.37%
Udemy, Inc.
$5.46
+1.37%
Trubridge Inc
$5.46
+1.37%
Stone Ridge 2049 Inflation-protected Longevity Income Etf
$5.46
+1.37%
Farmers National Banc Corp
$5.46
+1.37%
Bbb Foods Inc.
$5.46
+1.37%
Spdr Ssga Us Eq Prem Inc Etf
$5.46
+1.37%